| Primary |
| Cytomegalovirus Infection |
37.5% |
| Bone Marrow Failure |
25.0% |
| Cmv Retinitis |
12.5% |
| Drug Allergy |
12.5% |
| Prophylaxis |
12.5% |
|
| Intestinal Perforation |
25.0% |
| Renal Failure |
25.0% |
| Respiratory Failure |
25.0% |
| Visual Acuity Reduced |
25.0% |
|
| Secondary |
| Drug Use For Unknown Indication |
43.8% |
| Hiv Infection |
24.8% |
| Mycobacterium Avium Complex Infection |
6.5% |
| Cytomegalovirus Infection |
4.8% |
| Antifungal Prophylaxis |
3.1% |
| Encephalitis Cytomegalovirus |
2.7% |
| Prophylaxis |
2.3% |
| General Symptom |
2.2% |
| Hypersensitivity |
2.2% |
| Opportunistic Infection Prophylaxis |
1.3% |
| Oesophageal Candidiasis |
1.1% |
| Genital Herpes |
0.8% |
| Antibiotic Prophylaxis |
0.7% |
| B-cell Unclassifiable Lymphoma Low Grade |
0.6% |
| Cytomegalovirus Viraemia |
0.6% |
| Infection Prophylaxis |
0.6% |
| Acute Lymphocytic Leukaemia Recurrent |
0.5% |
| Prophylaxis Against Gastrointestinal Ulcer |
0.5% |
| Diffuse Large B-cell Lymphoma |
0.5% |
| Pneumocystis Jirovecii Pneumonia |
0.4% |
|
| Vomiting |
39.3% |
| Staphylococcal Infection |
9.8% |
| Staphylococcal Sepsis |
9.8% |
| Haemodialysis |
6.6% |
| Toxic Epidermal Necrolysis |
6.6% |
| Drug Ineffective |
3.3% |
| Renal Disorder |
3.3% |
| Uveitis |
3.3% |
| Blood Amylase Increased |
1.6% |
| Cytomegalovirus Test Positive |
1.6% |
| Encephalitis Cytomegalovirus |
1.6% |
| Mental Status Changes |
1.6% |
| Pathogen Resistance |
1.6% |
| Pyrexia |
1.6% |
| Staphylococcus Test Positive |
1.6% |
| Thrombotic Microangiopathy |
1.6% |
| Toxic Encephalopathy |
1.6% |
| Urine Output Decreased |
1.6% |
| Visual Acuity Reduced |
1.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
22.1% |
| Infection Prophylaxis |
11.6% |
| Prophylaxis |
10.3% |
| Hiv Infection |
9.8% |
| Bone Marrow Conditioning Regimen |
6.5% |
| Acute Myeloid Leukaemia |
6.4% |
| Prophylaxis Against Graft Versus Host Disease |
5.9% |
| Antifungal Prophylaxis |
3.7% |
| Premedication |
3.5% |
| Aplastic Anaemia |
2.9% |
| Graft Versus Host Disease |
2.9% |
| Antiviral Prophylaxis |
2.8% |
| Antibiotic Prophylaxis |
2.0% |
| Cytomegalovirus Infection |
1.9% |
| Acute Graft Versus Host Disease |
1.5% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.5% |
| Acute Lymphocytic Leukaemia |
1.2% |
| Mycobacterium Avium Complex Infection |
1.2% |
| Encephalitis Cytomegalovirus |
1.2% |
| Convulsion Prophylaxis |
1.1% |
|
| Pneumonia |
14.8% |
| Platelet Count Decreased |
10.2% |
| Epstein-barr Virus Associated Lymphoproliferative Disorder |
6.5% |
| White Blood Cell Count Decreased |
6.5% |
| Hypokalaemia |
5.6% |
| Pyrexia |
5.6% |
| Sepsis |
5.6% |
| Cystitis Haemorrhagic |
4.6% |
| Infection |
4.6% |
| Acute Graft Versus Host Disease In Skin |
3.7% |
| Cytomegalovirus Test Positive |
3.7% |
| Staphylococcal Infection |
3.7% |
| Therapeutic Response Decreased |
3.7% |
| Visual Impairment |
3.7% |
| Weight Decreased |
3.7% |
| Abdominal Pain Upper |
2.8% |
| Febrile Neutropenia |
2.8% |
| Hepatic Function Abnormal |
2.8% |
| Interstitial Lung Disease |
2.8% |
| Pseudomonal Sepsis |
2.8% |
|
